Melanotan 2

Overall Health Benefits of Melanotan 2

• Treats erectile dysfunction [1-9]
• Helps lose weight [10-17]
• Prevents cancer [18-19]
• Prevents heart disease [20-22]
• Promotes healthy brain [23-28]
• Treats inflammatory disorders [29-30]
• Improves blood sugar levels and treats symptoms of diabetes [31-33]
• Treats alcohol abuse disorder [34-37]

What is Melanotan 2?

Melanotan 2 or MT-2 is a synthetic analog of the peptide hormone α-melanocyte-stimulating hormone. It is used to induce erections in men with erectile dysfunction and increase sexual arousal in women.

How Melanotan 2 Works?

Melanotan 2 is similar to the melanocyte-stimulating hormone, a substance found in your body that is responsible for the production of skin-darkening pigments called melanin. It works by binding with melanocortin receptors. Melanotan 2 binds to MC-1R to stimulate the darkening of the skin and hair. It also stimulates penile erection by binding to MC-4R.

Chemical Structure of Melanotan 2

Research on Melanotan 2

Treats Erectile Dysfunction

Evidence suggests that MT-2 has beneficial effects on sexual function:

1. In men with psychogenic erectile dysfunction, MT-2 treatment successfully resulted in penile erections. [1]
2. In men with erectile dysfunction (ED), MT-2 treatment led to increased sexual desire and penile erection even without any sexual stimulation. [2-3]
3. In rats, MT-2 induced erections sufficient for sexual intercourse. [4]
4. In rabbits, intravenous injection of MT-2 resulted in increased pressure within the erectile tissue. [5]
5. In normal male volunteers, administration of MT-2 produced spontaneous, penile erections after 1-5 hours. [6]
6. A rat study showed that MT-2 was effective for skin tanning and could be used to prevent sunlight-induced skin cancers. [7]
7. In men with psychogenic erectile dysfunction, MT-2 was effective in inducing an erection. [8]
8. In male rats, MT-2 injection successfully induced penile erection. [9]

Helps Lose Weight

Studies also found that MT-2 has fat-burning effects that can be beneficial in overweight and obese individuals:

1. In obese rats, MT-2 treatment resulted in increased fat breakdown. [10]
2. In rats, peripheral MT-2 treatment led to weight loss. [11]
3. A study showed that MT-2 could safely reduce fat mass without inducing apoptosis (programmed cell death) in rats. [12]
4. A study showed that continued MT-2 application consistently induced weight and fat loss in rat subjects. [13]
5. In rats, MT-2 treatment effectively reduced body mass without long-term food restrictions. [14]
6. A rat study also found that MT-2 treatment decreased food intake and increased energy expenditure. [15]
7. A study suggested that MT-2 treatment could be effective in treating obesity by stimulating leptin and melanocortin pathways in the brain.[16-17]

Prevents Cancer

Studies show that MT-2 also exerts anti-cancer properties that can help protect against skin cancer:

1. A study suggested that MT-2 application could prevent sunlight-induced skin cancer. [18]
2. In healthy volunteers, it was found that MT-1 was safe and effective for skin tanning when combined with solar UV light, and has protective effects against sunlight-induced skin cancer. [19]

Prevents Heart Disease

MT-2 has also been shown to exert cardioprotective properties:

1. In mice, MT-2 treatment had therapeutic benefits in pre-established atherosclerosis (plaque formation within the heart arteries) by limiting inflammation and promoting vascular endothelial function. [20]
2. In patients with coronary heart disease, it was found that they have altered levels of MT-2 in the heart. [21]
3. In an animal model of myocardial ischemia (inadequate blood flow to the heart), MT-2 treatment improved heart function by reducing oxidative stress and programmed cell death. [22]

Promotes Healthy Brain

Evidence suggests that MT-2 is essential for optimal brain function:

1. In rats, it was shown that treatment with melanocortin receptor agonists like melanotan 2 could regulate the activity of central dopamine neurons in the brain. [23]
2. In a mouse model of stroke, MT-2 treatment improved working memory. [24]
3. In rats, it was found that MT-2 levels were impaired in the group with cognitive dysfunction. [25]
4. A study reported that MT-2 may potentially treat mental disorders such as depression and anxiety. [26]
5. In rats, MT-2 promoted nerve regeneration in the brain and protected against injury. [27]
6. In a maternal immune activation (MIA) mouse model of autism, MT-2 administration reversed the negative behaviors associated with autism spectrum disorder (ASD). [28]

Treats Inflammatory Disorders

A good deal of evidence supports the anti-inflammatory properties of MT-2:

1. In a mouse model of stroke, MT-2 treatment inhibited brain inflammation. [29]
2. In mice with plaque build-up within the heart, MT-2 inhibited plaque inflammation and promoted vascular endothelial function. [30]

Improves Blood Sugar Levels and Treats Symptoms of Diabetes

Studies suggest that MT-2 can help stabilize blood sugar levels and treat diabetic symptoms:

1. In rats, injection of MT-2 reduced food intake and body weight and improved insulin sensitivity. [31]
2. In rats fed with a high-fat diet, MT-2 reversed diabetes by suppressing the hypothalamic-pituitary-adrenal axis. [32]
3. In mice, MT-2 and leptin administration induced increased glucose uptake in skeletal muscles. [33]

Treats Alcohol Abuse Disorder

MT-2 has also been found to significantly reduce alcohol intake which makes it beneficial for those with alcohol abuse disorder:

1. In male rats who were subjected to long-term voluntary alcohol consumption, MT-2 reduced alcohol intake. [34]
2. In mice, MT-2 administration reduced binge-like ethanol drinking. [35]
3. In a mouse model of alcohol abuse disorder, low-dose MT-2 reduced binge-ethanol drinking. [36]
4. In rats, MT-2 administration through injections at the border of the central amygdala nucleus and the basolateral amygdala resulted in reduced alcohol intake while increasing their water intake. [37]

Associated Side Effects of Melanotan 2

Melanotan 2 side effects are very uncommon. There have been some side effects associated with the use of this drug wherein the patient had one of the issues listed below at some point while being on melanotan 2. However, these side effects weren’t confirmed to be associated with the treatment and could have been a coincidence and not related to the use of melanotan 2. Despite this, it was listed as a side effect associated with melanotan 2 even though these associated side effects are very uncommon.

Side effects associated with melanotan 2 may include the following:

• Agitation
• Darkening of the skin
• Facial flushing
• Fatigue
• Increased blood pressure
• Increased heart rate
• Increased moles and freckles
• Increased sweating
• Loss of appetite
• Nausea
• Spontaneous erections
• Vomiting

References

1. Wessells H, Fuciarelli K, Hansen J, Hadley ME, Hruby VJ, Dorr R, Levine N. Synthetic melanotropic peptide initiates erections in men with psychogenic erectile dysfunction: double-blind, placebo controlled crossover study. J Urol. 1998 Aug;160(2):389-93. PMID: 9679884.
2. Wessells H, Levine N, Hadley ME, Dorr R, Hruby V. Melanocortin receptor agonists, penile erection, and sexual motivation: human studies with Melanotan II. Int J Impot Res. 2000 Oct;12 Suppl 4:S74-9. doi: 10.1038/sj.ijir.3900582. PMID: 11035391.
3. Wessells H, Gralnek D, Dorr R, Hruby VJ, Hadley ME, Levine N. Effect of an alpha-melanocyte stimulating hormone analog on penile erection and sexual desire in men with organic erectile dysfunction. Urology. 2000 Oct 1;56(4):641-6. doi: 10.1016/s0090-4295(00)00680-4. PMID: 11018622.
4. Giuliano F, Clément P, Droupy S, Alexandre L, Bernabé J. Melanotan-II: Investigation of the inducer and facilitator effects on penile erection in anaesthetized rat. Neuroscience. 2006;138(1):293-301. doi: 10.1016/j.neuroscience.2005.11.008. Epub 2005 Dec 19. PMID: 16360286.
5. Vemulapalli R, Kurowski S, Salisbury B, Parker E, Davis H. Activation of central melanocortin receptors by MT-II increases cavernosal pressure in rabbits by the neuronal release of NO. Br J Pharmacol. 2001;134(8):1705-1710. doi:10.1038/sj.bjp.0704437.
6. Dorr RT, Lines R, Levine N, Brooks C, Xiang L, Hruby VJ, Hadley ME. Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study. Life Sci. 1996;58(20):1777-84. doi: 10.1016/0024-3205(96)00160-9. PMID: 8637402.
7. Lan EL, Ugwu SO, Blanchard J, Fang X, Hruby VJ, Sharma S. Preformulation studies with melanotan-II: a potential skin cancer chemopreventive peptide. J Pharm Sci. 1994 Aug;83(8):1081-4. doi: 10.1002/jps.2600830805. PMID: 7983590.
8. Wessells H, Fuciarelli K, Hansen J, Hadley ME, Hruby VJ, Dorr R, Levine N. Synthetic melanotropic peptide initiates erections in men with psychogenic erectile dysfunction: double-blind, placebo controlled crossover study. J Urol. 1998 Aug;160(2):389-93. PMID: 9679884.
9. Available from https://nyaspubs.onlinelibrary.wiley.com/doi/10.1111/j.1749-6632.2003.tb03166.x.
10. Li G, Zhang Y, Wilsey JT, Scarpace PJ. Unabated anorexic and enhanced thermogenic responses to melanotan II in diet-induced obese rats despite reduced melanocortin 3 and 4 receptor expression. J Endocrinol. 2004 Jul;182(1):123-32. doi: 10.1677/joe.0.1820123. PMID: 15225137.
11. Strader AD, Shi H, Ogawa R, Seeley RJ, Reizes O. The effects of the melanocortin agonist (MT-II) on subcutaneous and visceral adipose tissue in rodents. J Pharmacol Exp Ther. 2007 Sep;322(3):1153-61. doi: 10.1124/jpet.107.123091. Epub 2007 Jun 13. PMID: 17567964.
12. Choi YH, Li C, Hartzell DL, Lin J, Della-Fera MA, Baile CA. MTII administered peripherally reduces fat without invoking apoptosis in rats. Physiol Behav. 2003 Jul;79(2):331-7. doi: 10.1016/s0031-9384(03)00118-5. PMID: 12834806.
13. Zhang Y, Collazo R, Gao Y, Li G, Scarpace PJ. Intermittent MTII application evokes repeated anorexia and robust fat and weight loss. Peptides. 2010;31(4):639-643. doi:10.1016/j.peptides.2009.12.019.
14. Côté I, Sakarya Y, Kirichenko N, et al. Activation of the central melanocortin system chronically reduces body mass without the necessity of long-term caloric restriction. Can J Physiol Pharmacol. 2017;95(2):206-214. doi:10.1139/cjpp-2016-0290.
15. Maria M. Glavas, Sandra E. Joachim, Shin J. Draper, M. Susan Smith, Kevin L. Grove, Melanocortinergic Activation by Melanotan II Inhibits Feeding and Increases Uncoupling Protein 1 Messenger Ribonucleic Acid in the Developing Rat, Endocrinology, Volume 148, Issue 7, 1 July 2007, Pages 3279–3287, https://doi.org/10.1210/en.2007-0184.
16. Available from https://www.researchgate.net/publication/24019710_The_Role_of_Leptin-Melanocortin_System_and_Human_Weight_Regulation_Lessons_from_Experiments_of_Nature.
17. Bjørbaek C, Hollenberg AN. Leptin and melanocortin signaling in the hypothalamus. Vitam Horm. 2002;65:281-311. doi: 10.1016/s0083-6729(02)65068-x. PMID: 12481551.
18. Lan EL, Ugwu SO, Blanchard J, Fang X, Hruby VJ, Sharma S. Preformulation studies with melanotan-II: a potential skin cancer chemopreventive peptide. J Pharm Sci. 1994 Aug;83(8):1081-4. doi: 10.1002/jps.2600830805. PMID: 7983590.
19. Dorr RT, Ertl G, Levine N, Brooks C, Bangert JL, Powell MB, Humphrey S, Alberts DS. Effects of a superpotent melanotropic peptide in combination with solar UV radiation on tanning of the skin in human volunteers. Arch Dermatol. 2004 Jul;140(7):827-35. doi: 10.1001/archderm.140.7.827. PMID: 15262693.
20. Rinne P, Silvola JM, Hellberg S, Ståhle M, Liljenbäck H, Salomäki H, Koskinen E, Nuutinen S, Saukko P, Knuuti J, Saraste A, Roivainen A, Savontaus E. Pharmacological activation of the melanocortin system limits plaque inflammation and ameliorates vascular dysfunction in atherosclerotic mice. Arterioscler Thromb Vasc Biol. 2014 Jul;34(7):1346-54. doi: 10.1161/ATVBAHA.113.302963. Epub 2014 May 1. PMID: 24790139.
21. Ekmekcioglu C, Thalhammer T, Humpeler S, Mehrabi MR, Glogar HD, Hölzenbein T, Markovic O, Leibetseder VJ, Strauss-Blasche G, Marktl W. The melatonin receptor subtype MT2 is present in the human cardiovascular system. J Pineal Res. 2003 Aug;35(1):40-4. doi: 10.1034/j.1600-079x.2003.00051.x. PMID: 12823612.
22. Han D, Wang Y, Chen J, Zhang J, Yu P, Zhang R, Li S, Tao B, Wang Y, Qiu Y, Xu M, Gao E, Cao F. Activation of melatonin receptor 2 but not melatonin receptor 1 mediates melatonin-conferred cardioprotection against myocardial ischemia/reperfusion injury. J Pineal Res. 2019 Aug;67(1):e12571. doi: 10.1111/jpi.12571. Epub 2019 Apr 12. PMID: 30903623.
23. Lindblom J, Kask A, Hägg E, Härmark L, Bergström L, Wikberg J. Chronic infusion of a melanocortin receptor agonist modulates dopamine receptor binding in the rat brain. Pharmacol Res. 2002 Feb;45(2):119-24. doi: 10.1006/phrs.2001.0913. PMID: 11846623.
24. Wang W, Guo DY, Lin YJ, Tao YX. Melanocortin Regulation of Inflammation. Front Endocrinol (Lausanne). 2019;10:683. Published 2019 Oct 9. doi:10.3389/fendo.2019.00683.
25. Bahna SG, Sathiyapalan A, Foster JA, Niles LP. Regional upregulation of hippocampal melatonin MT2 receptors by valproic acid: therapeutic implications for Alzheimer’s disease. Neurosci Lett. 2014 Jul 25;576:84-7. doi: 10.1016/j.neulet.2014.05.056. Epub 2014 Jun 5. PMID: 24909617.
26. Comai S, Gobbi G. Unveiling the role of melatonin MT2 receptors in sleep, anxiety and other neuropsychiatric diseases: a novel target in psychopharmacology. J Psychiatry Neurosci. 2014;39(1):6-21. doi:10.1503/jpn.130009.
27. The potent melanocortin receptor agonist melanotan-II promotes peripheral nerve regeneration and has neuroprotective properties in the rat. Ter Laak, M.P., Brakkee, J.H., Adan, R.A., Hamers, F.P., Gispen, W.H. Eur. J. Pharmacol. (2003).
28. Minakova E, Lang J, Medel-Matus JS, Gould GG, Reynolds A, Shin D, Mazarati A, Sankar R. Melanotan-II reverses autistic features in a maternal immune activation mouse model of autism. PLoS One. 2019 Jan 10;14(1):e0210389. doi: 10.1371/journal.pone.0210389. PMID: 30629642; PMCID: PMC6328175.
29. Tsai TH, Lin CJ, Chua S, Chung SY, Yang CH, Tong MS, Hang CL. Melatonin attenuated the brain damage and cognitive impairment partially through MT2 melatonin receptor in mice with chronic cerebral hypoperfusion. Oncotarget. 2017 Aug 22;8(43):74320-74330. doi: 10.18632/oncotarget.20382. Erratum in: Oncotarget. 2020 Sep 22;11(38):3558. PMID: 29088788; PMCID: PMC5650343.
30. Rinne P, Silvola JM, Hellberg S, Ståhle M, Liljenbäck H, Salomäki H, Koskinen E, Nuutinen S, Saukko P, Knuuti J, Saraste A, Roivainen A, Savontaus E. Pharmacological activation of the melanocortin system limits plaque inflammation and ameliorates vascular dysfunction in atherosclerotic mice. Arterioscler Thromb Vasc Biol. 2014 Jul;34(7):1346-54. doi: 10.1161/ATVBAHA.113.302963. Epub 2014 May 1. PMID: 24790139.
31. Banno R, Arima H, Sato I, Hayashi M, Goto M, Sugimura Y, Murase T, Oiso Y. The melanocortin agonist melanotan II increases insulin sensitivity in OLETF rats. Peptides. 2004 Aug;25(8):1279-86. doi: 10.1016/j.peptides.2004.05.007. PMID: 15350695.
32. Zhou J, Zhang J, Luo X, Li M, Yue Y, Laudon M, Jia Z, Zhang R. Neu-P11, a novel MT1/MT2 agonist, reverses diabetes by suppressing the hypothalamic-pituitary-adrenal axis in rats. Eur J Pharmacol. 2017 Oct 5;812:225-233. doi: 10.1016/j.ejphar.2017.07.001. Epub 2017 Jul 4. PMID: 28687198.
33. Toda C, Shiuchi T, Lee S, Yamato-Esaki M, Fujino Y, Suzuki A, Okamoto S, Minokoshi Y. Distinct effects of leptin and a melanocortin receptor agonist injected into medial hypothalamic nuclei on glucose uptake in peripheral tissues. Diabetes. 2009 Dec;58(12):2757-65. doi: 10.2337/db09-0638. Epub 2009 Sep 14. PMID: 19752162; PMCID: PMC2780865.
34. Vengeliene V, Noori HR, Spanagel R. Activation of Melatonin Receptors Reduces Relapse-Like Alcohol Consumption. Neuropsychopharmacology. 2015 Dec;40(13):2897-906. doi: 10.1038/npp.2015.143. Epub 2015 May 21. PMID: 25994077; PMCID: PMC4864625.
35. Olney JJ, Sprow GM, Navarro M, Thiele TE. The protective effects of the melanocortin receptor (MCR) agonist, melanotan-II (MTII), against binge-like ethanol drinking are facilitated by deletion of the MC3 receptor in mice. Neuropeptides. 2014;48(1):47-51. doi:10.1016/j.npep.2013.11.001.
36. Navarro M, Carvajal F, Lerma-Cabrera JM, Cubero I, Picker MJ, Thiele TE. Evidence that Melanocortin Receptor Agonist Melanotan-II Synergistically Augments the Ability of Naltrexone to Blunt Binge-Like Ethanol Intake in Male C57BL/6J Mice. Alcohol Clin Exp Res. 2015 Aug;39(8):1425-33. doi: 10.1111/acer.12774. Epub 2015 Jun 24. PMID: 26108334; PMCID: PMC4515169.
37. York DA, Boghossian S, Park-York M. Melanocortin activity in the amygdala influences alcohol intake. Pharmacol Biochem Behav. 2011 Mar;98(1):112-9. doi: 10.1016/j.pbb.2010.12.010. Epub 2010 Dec 15. PMID: 21167196.